
RxSight (RXST) Stock Forecast & Price Target
RxSight (RXST) Analyst Ratings
Bulls say
RxSight Inc. reported operating expenses of $36.4 million, an increase of $2.0 million year-over-year, while revenue in the third quarter surpassed consensus expectations, prompting management to raise its guidance. The company is expected to sustain double-digit growth, fueled by increased utilization from a growing installed base of light adjustable lens technology (LDD), along with strategic initiatives aimed at enhancing lens volume engagement. Furthermore, management has upgraded gross margin guidance to a range of 76-77% for 2025, signaling potential for improved profitability alongside its commitment to managing operating expenses.
Bears say
RxSight Inc. has experienced declining utilization of its light adjustable lenses (LALs), with monthly utilization dropping to 8.0 LALs per light delivery device (LDD) in 3Q25, reflecting a downward trend both quarter-over-quarter and year-over-year. Revenue declined to $30.3 million, marking a 14% decrease year-over-year, and LDD placements fell significantly by 68% year-over-year and 38% quarter-over-quarter, suggesting disappointing commercial execution and limited market adoption. Additionally, increased competition in the intraocular lens market, along with the potential for a dilutive financing round, further exacerbates the risks associated with the company's future performance.
This aggregate rating is based on analysts' research of RxSight and is not a guaranteed prediction by Public.com or investment advice.
RxSight (RXST) Analyst Forecast & Price Prediction
Start investing in RxSight (RXST)
Order type
Buy in
Order amount
Est. shares
0 shares